Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company was founded in 2002 and is based in Shanghai, China.
Metrics to compare | 688336 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688336PeersSector | |
---|---|---|---|---|
P/E Ratio | 42.8x | 35.3x | −0.5x | |
PEG Ratio | 0.44 | 0.43 | 0.00 | |
Price/Book | 5.4x | 2.4x | 2.6x | |
Price / LTM Sales | 24.7x | 7.1x | 3.3x | |
Upside (Analyst Target) | −1.9% | 7.3% | 43.4% | |
Fair Value Upside | Unlock | 12.0% | 7.1% | Unlock |